Results

1–10 of 10 results for suprachoroidal drug delivery

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Post Hoc Analysis of Suprachoroidal CLS-TA Versus Real-World Rescue Therapies for Uveitic Macular Edema: Safety and Visual Function
Steven Yeh, MD
Annual Meeting Talks
2021
Suprachoroidal Delivery of Small Molecule Suspensions: Pre-Clinical Results Correlate to Clinical Trial Outcomes
James C. Major, MD, PhD FACS FASRS
Annual Meeting Talks
2021
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Annual Meeting Talks
2021
Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension: Results From the Phase 3 PEACHTREE Clinical Trial
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2020
Post Hoc Analysis of Clinical Suprachoroidal Injection Experience for Non-infectious Uveitis
Shree K. Kurup, MD
Annual Meeting Talks
2020
Post Hoc Analysis of Suprachoroidal Injection Experience Across Retinal Disease Indications
Christopher R Henry, MD
Annual Meeting Talks
2020
Suprachoroidal CLS-AX (axitinib injectable suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
David M. Brown, MD
Annual Meeting Talks
2020
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Updates from the Field
2021
A Phase 2 Safety and Efficacy Trial of AU-011, a Virus-Like Drug Conjugate, With Dose Escalation and Randomized Masked Expansion in Uveal Melanoma
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2021